Janux Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Janux Therapeutics, Inc. (JANX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $11.22 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-06
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $11.19, a 74.31% decline year-over-year.
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $43.55, a 436.99% increase year-over-year.
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $8.11, a 20.57% decline year-over-year.
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $10.21, a 27.18% decline year-over-year.
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $38.10, a 237.17% increase from fiscal 2024.
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $11.30, a 12.77% increase from fiscal 2023.
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $10.02, a 18.87% decline from fiscal 2022.
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $12.35, a 54.18% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.22 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $11.19 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $38.10 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $38.52 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $39.26 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | $43.55 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | $11.30 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $10.86 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | $9.14 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | $8.11 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $10.02 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $10.09 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | $10.09 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | $10.21 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $12.35 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $12.52 10-Q · filed 2023-11-07 | |||
| 2022-06-30 | $12.65 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | $14.02 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $8.01 10-K · filed 2023-03-10 | |||
| 2021-09-30 | $7.83 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | $6.45 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | $3.12 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $0.44 10-K · filed 2022-03-18 | |||
| 2020-09-30 | $0.43 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | $0.09 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |